Lyra Therapeutics (LYRA) Appoints Jim Tobin to its Board

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the appointment of Jim Tobin to its Board of Directors (BOD). The former President and Chief Executive Officer of both Boston Scientific Corporation and Biogen Inc., Mr. Tobin currently serves as Chairman of the Board at TransMedics, Inc. and Board Member of each of Globus Medical Inc., a publicly traded company, as well as Impulse Dynamics and Xenter Medical.

"Jim holds unparalleled experience leading public biopharmaceutical and medical device companies with products across therapeutic areas that have made a meaningful impact on the lives of patients around the world," said Maria Palasis, PhD, President and Chief Executive Officer of Lyra Therapeutics. "We look forward to his valuable insight as we continue progressing our novel pipeline candidates, LYR-210 and LYR-220, through clinical development and toward potential commercialization."

Mr. Tobin served as President and CEO of Boston Scientific from March 1999 to July 2009. Before joining Boston Scientific, he was President and CEO of Biogen, which he joined as President and Chief Operating Officer (COO) in 1994 and became President and CEO in 1997. He also served on Biogen's Board of Directors. Previously, Mr. Tobin spent 22 years at Baxter International, rising from financial analyst to President and COO. Mr. Tobin has served on the board of over 20 companies and was a Lieutenant in the U.S. Navy from 1968 to 1972. He holds an MBA from Harvard Business School and an a.b. from Harvard College.

"Lyra has the potential to change the treatment landscape for millions of chronic rhinosinusitis (CRS) patients who have failed medical management," said Mr. Tobin. "I look forward to helping shape Lyra's promising future with the leadership team and Board."

You May Also Be Interested In

• Patrick Bombach resigns from Mobileye board amid Intel departure
• Zealand Pharma sells rusfertide royalty rights to Royalty Pharma for $100M
• H.B. Fuller receives $1.1B-$1.2B bid for building adhesives unit